TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01325376

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Technology assisted health behavior
Description: Web-based interactive program using an hpod sensor that tracks physical activity as well as biometric parameters into the iWell server and is transmitted to the internet site via the users PC. Also serves as a social networking site.
Study: NCT01851252

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Methacetin (with Breath testing device)
Description: The methacetin is enriched with carbon 13, a stable non- radioactive isotope, and has been found to be safe in hundreds of studies. The material is very similar to acetominophen. 75 milligrams (mm) of this material pre- dissolved in water are used. This material undergoes rapid metabolism by the liver.
Study: NCT01050530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-41061
Description: Once-daily oral administration of OPC-41061 at 7.5 mg after breakfast for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once-daily oral administration of placebo after breakfast for 7 days
Study: NCT04190992

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-based & personalized breast reconstruction surgery decision aid
Description: This decision aid contains information regarding surgical options, including breast reconstruction and mastectomy, such as the advantages and disadvantages, the complication probabilities of each option, a value clarification exercise for the patient's self-evaluation, and a summary of the participant's decision-making process.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: A pamphlet introduce the introduction of types of surgery
Study: NCT03165422

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study: NCT01325376

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Self directed
Description: Receives support and encouragement with minimal contact. Receives printed lifestyle guidelines with diet and physical activity recommendations.
Study: NCT01119118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054
Description: All patients will be treated with ZD4054 at 10 mg PO daily, repeated in four week cycles (1 cycle = 28 days). All patients will initially undergo NaF and FDG PET/CT and MRI imaging at baseline (scan#1), and then again after 4 weeks (scan#2) of ZD4054 exposure. Subsequently, ZD4054 will be held for 2 weeks followed by the final NaF and FDG-PET/CT and MRI acquisition (scan#3). After the final PET/MRI is obtained, patients will resume ZD4054 and be assessed for safety prior to each new cycle of therapy. Standard disease evaluation assessments will be conducted after cycle#3, and repeated after every third cycle (sooner if clinically indicated). Therapy will continue until radiographical/clinical disease progression or unacceptable toxicity
Study: NCT01263366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Approximately 1.6 or 4.6 mL of a 400 mM norepinephrine solution will be applied topically to a portion of the radiation treatment field prior to each radiation treatment (20-33 treatments)
Study: NCT03939429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QPX2015
Description: antibiotic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo comparator
Study: NCT01867593

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-11 methionine PET
Study: NCT01358617

Intervention type: OTHER
Intervention: diagnostic laboratory biomarker analysis
Description: Correlative studies
Study: NCT02296112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trametinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03579277

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radial Forearm Free Flap
Description: Subjects in this arm will undergo a radial forearm free flap.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ulnar Forearm Free Flap
Description: Subjects in this arm will undergo an ulnar forearm free flap.
Study: NCT02296112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT03331796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active rTMS (Bilateral DLPFC)
Description: TMS Stimulation Parameters for the active DLPFC rTMS intervention group will be: 10 Hz, 4-second train duration and 11-second inter-train interval. During each session, 2,000 pulses will be applied for each hemisphere (for a total of 4,000 pulses per session). Participants will receive 20 sessions (1 or 2 sessions per day, M-F).
Study: NCT03243552

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-DOPA versus Placebo
Description: Participants will be randomized in a blocked schedule to yield 1:1 L-DOPA: placebo assignment.
Study: NCT04190992

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: A pamphlet introduce the introduction of types of surgery
Study: NCT00291317

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RT 300-P FES Cycle
Description: Participants exercised using functional electrical stimulation cycling (FES) using the RT 300-P FES cycle (Restorative Therapies, Baltimore, MD). Children were scheduled to attend three cycling sessions per week on non-consecutive days for up to 30 minutes per session over a 9 month period. The intervention was provided at Children's Specialized Hospital in Mountainside, and families were required to provide their own transportation. During the study, the participants continued to participate in their standard, primary rehabilitation program.
Study: NCT00470535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Oral

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative Study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative Study
Study: NCT00917774

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard LPS flex TKA
Description: TKA by Standard LPS flex TKA
Study: NCT03331796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active rTMS (Bilateral LPC)
Description: TMS Stimulation Parameters for the active LPC rTMS intervention group will be: 10 Hz, 4-second train duration and 11-second inter-train interval. During each session, 2,000 pulses will be applied for each hemisphere (for a total of 4,000 pulses per session). Participants will receive 20 sessions (1 or 2 sessions per day, M-F).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo rTMS (Inactive)
Description: For the Placebo rTMS (Inactive) group, the participant will wear scalp electrodes through which a low voltage, low electric current (2-20mA at no more than 100V) is passed to mimic the sensation of receiving actual rTMS. Participants will receive 20 sessions (1 or 2 sessions per day, M-F).
Study: NCT02957175

Intervention type: OTHER
Intervention: Immunophenotyping
Description: Multiplex assays for screening pro- and anti-inflammatory markers and RNA will be analysed using a next generation sequencing approach

Intervention type: OTHER
Intervention: Immunophenotyping
Description: Multiplex assays for screening pro- and anti-inflammatory markers and RNA will be analysed using a next generation sequencing approach
Study: NCT01466192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-424 (generic name:Telaprevir)
Description: 750mg q8h for 12 weeks
Study: NCT00917774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gender specific LPS -Flex TKA
Description: Total knee design created specific for female patients
Study: NCT02728700

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo HSCT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO
Study: NCT02832011

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: olive oil
Description: The infants fed with olive oil will have received same amount of calorie with infants who will receive eoprotin-fortified breast milk.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: olive oil
Description: The infants fed with olive oil will have received same amount of calorie with infants who will receive eoprotin-fortified breast milk.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Eoprotin
Description: Low birth weight infants are premature infants that born with birth weight less than 1500 g. Because these infants have low birth weight, weight gain can be increased by fortifying breast milk after post-natal 7 with eoprotin.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Eoprotin
Description: Low birth weight infants are premature infants that born with birth weight less than 1500 g. Because these infants have low birth weight, weight gain can be increased by fortifying breast milk after post-natal 7 with eoprotin.
Study: NCT00399061

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systane, Optive, Restasis
Description: Systane 30ml (in the eye) instill one drop twice a day in morning and evening Optive 15ml (in the eye) instill one drop twice a day in morning and evening Restasis 0.4ml (in the eye) instill one drop twice a day in morning and evening more frequently if needed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systane, Optive, Restasis
Description: Systane 30ml (in the eye) instill one drop twice a day in morning and evening Optive 15ml (in the eye) instill one drop twice a day in morning and evening Restasis 0.4ml (in the eye) instill one drop twice a day in morning and evening more frequently if needed
Study: NCT00414518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate/Emtricitabine
Description: 300 mg Tenofovir disoproxil fumarate/ 200 mg emtricitabine tablet taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate/Emtricitabine
Description: 300 mg Tenofovir disoproxil fumarate/ 200 mg emtricitabine tablet taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir
Description: Three 400 mg lopinavir/ 100 mg ritonavir soft gel capsules taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir
Description: Three 400 mg lopinavir/ 100 mg ritonavir soft gel capsules taken orally twice daily
Study: NCT03243552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-DOPA versus Placebo
Description: Participants will be randomized in a blocked schedule to yield 1:1 L-DOPA: placebo assignment.
Study: NCT01466192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 400 - 1000 mg/day based on body weight for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b
Description: 1.5mcg/kg/week for 24 weeks
Study: NCT02617550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189)
Description: Vericiguat up-titration from 2.5 mg to 10 mg in an interval of 14 +/- 3 days: 2.5 mg vericiguat for 14 +/-3 days given as 2 x 1.25 mg tablets followed by 5 mg vericiguat for 14 +/-3 days given as 1 x 5 mg tablet followed by 10 mg vericiguat for 14 +/-3 days given as 2 x 5 mg tablets
Study: NCT04370353

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cocoa flavanols
Description: Flavonoid-rich cocoa powder, containing 100mg total flavanols per 316mg.
Study: NCT02617550

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 14 +/-3 days given as 1 or 2 tablets \[o.d.\].

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitroglycerin
Description: 0.4 mg nitroglycerin spray administered at 2.5 hours before treatment (vericiguat \[trough\] or placebo) on day 12, day 26 and day 40 at 4 hours after treatment (vericiguat \[peak\] or placebo) on day 13, day 27 and day 41

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Description: 0.4 mg nitroglycerin spray administered at 2.5 hours before treatment (vericiguat \[trough\] or placebo) on day 12, day 26 and day 40 at 4 hours after treatment (vericiguat \[peak\] or placebo) on day 13, day 27 and day 41
Study: NCT01588912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine
Description: If virologic response, which means HBV DNA \< 50 IU/mL, is shown at 24 weeks, telbivudine monotherapy is maintained and in the event that virologic response is not shown, tenofovir add-on therapy is done

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: If virologic response, which means HBV DNA \< 50 IU/mL, is shown at 24 weeks, telbivudine monotherapy is maintained and in the event that virologic response is not shown, tenofovir add-on therapy is done

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Maintain the entecavir through the study period
Study: NCT02084628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoxetate disodium (Eovist/Primovist, BAY86-4873)
Description: Participants to receive single dose of Eovist/Primovist as a manual injection at a dose of 0.1 milliliter per kilogram (mL/kg) body weight (BW) (0.025 millimole \[mmol\]/kg BW), followed by a flush of at least 5 mL saline (sodium chloride 0.9 percent \[%\] solution) manually.
Study: NCT05854875

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Roux en Y gastric bypass
Description: Laparoscopic RYGBP included the creation of a small gastric pouch, with a 200cm biliopancreatic limb and a 150cm alimentary limb.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux en Y gastric bypass with fundus resection
Description: Laparoscopic RYGBP included the creation of a small gastric pouch, with a 200cm biliopancreatic limb and a 150cm alimentary limb. Fundus resection is further applied in this arm.
Study: NCT04174313

Intervention type: DIAGNOSTIC_TEST
Intervention: CT scan
Description: Mechanical variables and PaO2/FiO2 were registered daily for 14 days or until initiating assisted ventilation. These data were obtained in passive mechanical conditions.~Ventilator-induced lung injury vortex was defined as a progressive increase in driving pressure (ΔP) as Vt remained constant or even decreased.~Refractory hypoxemia was defined as PaO2/FiO2 \<100 despite the optimization of mechanical ventilation and prone positioning.
Study: NCT04288622

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weekly standardised, personalised feedback
Description: The ESM-F group will receive standardised ESM-derived feedback immediately followed the weekly ESM data collection procedure, totalling 6 times in the entire intervention period. The feedback will be provided by the researcher in the format of written report and verbal explanation. The feedback on participants' momentary affective state in specific daily life contexts and the association with depressive symptoms will be given. The changes in positive affect level and the number of depressive complaints over the course of the ESM intervention will be shown.
Study: NCT04370353

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: Microcrystalline filler, containing 0mg total flavanols.
Study: NCT03243552

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Skills Training
Description: ASD participants will be enrolled concurrently in a 16-week manualized, structured, group-based, social skills training program (PEERS).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Skills Training
Description: ASD participants will be enrolled concurrently in a 16-week manualized, structured, group-based, social skills training program (PEERS).
Study: NCT03817658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: First stage：~Concurrent chemoradiotherapy:~Cisplatin：25-30mg/m2 ivgtt d1;Capecitabine：800mg/m2, bid d1-5，qw，5weeks；Synchronous radiotherapy：1.8-2Gy/d，5d/W，45-50Gy。 Consolidation treatment： Cisplatin： 60-75mg/m2 ivgtt d1 Capecitabine：1000mg/m2, bid d1-14，q3w 6weeks。~Second stage:~SHR-1210 was administered intravenously (no prophylactic use), a fixed dose of 200 mg, and 3 mg/kg for subjects with a baseline weight \<50 kg. Each infusion for 30 min (not less than 20 min, no more than 60 min), once every 2 weeks, 1 cycle every 4 weeks, the cumulative longest medication period is 12 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: First stage：~Concurrent chemoradiotherapy:~Cisplatin：25-30mg/m2 ivgtt d1;Capecitabine：800mg/m2, bid d1-5，qw，5weeks；Synchronous radiotherapy：1.8-2Gy/d，5d/W，45-50Gy。 Consolidation treatment： Cisplatin： 60-75mg/m2 ivgtt d1 Capecitabine：1000mg/m2, bid d1-14，q3w 6weeks。~Second stage:~Placebo was administered intravenously (no prophylactic use), a fixed dose of 200 mg, and 3 mg/kg for subjects with a baseline weight \<50 kg. Each infusion for 30 min (not less than 20 min, no more than 60 min), once every 2 weeks, 1 cycle every 4 weeks, the cumulative longest medication period is 12 months.
Study: NCT02496663

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Elastography
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Necitumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Given PO
Study: NCT04953793

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAY SUCCESS
Description: TAY SUCCESS stands for transition age youth supported, comprehensive cognitive enhancement and social skills. The cognitive-behavioral intervention teaches a number of strategies for executive functioning, social cognitive functioning and social communication.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care involved the typical vocational supportive education program delivered in the educational setting
Study: NCT04675320

Intervention type: BIOLOGICAL
Intervention: blood samples
Description: Blood sampling during PARP inhibitor therapy

Intervention type: BIOLOGICAL
Intervention: blood samples
Description: Blood sampling during PARP inhibitor therapy
Study: NCT03195959

Intervention type: OTHER
Intervention: Hypoxia and Hyperoxia
Description: 10 minutes of breathing a gas mixture with FiO2 0.16 via a tight fitting mask. After 10 minutes of breathing ambient air (normoxia), patients were exposed to hyperoxia (FiO2 1.0) for 10 minutes.

Intervention type: OTHER
Intervention: Hypoxia and Hyperoxia
Description: 10 minutes of breathing a gas mixture with FiO2 0.16 via a tight fitting mask. After 10 minutes of breathing ambient air (normoxia), patients were exposed to hyperoxia (FiO2 1.0) for 10 minutes.
Study: NCT00189605

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perc-DLR/Perc-DLG
Description: Device technique will be used per IFU
Study: NCT01194206

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: At least 3 gold standard Cyberknife fiducials will be placed in the liver w/in 6 cm of the tumor for image guidance during radiation therapy. At least 1 wk will elapse between fiducial placement and tx planning simulation to allow for fiducial settling and any migration.The full radiation tx will be given ideally in 3 consecutive days. In any case there must be a minimum of 24 hrs between fractions and all 3 fractions will be delivered w/in 14 days. The dose to at least 95% of the tumor will be 37.5 Gy total in 12.5 Gy fractions.
Study: NCT00873548

Intervention type: DEVICE
Intervention: PFNA-Asia
Description: The operation is performed under regional or general anesthesia and involves the following main steps:~1. Positioning of the patient~2. Definition of the CCD-angle~3. Fracture reduction~4. Determination of the nail diameter~5. Incision~6. Insertion of the device
Study: NCT00189605

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopy guided transforaminal epidural steroid injection (TFESI)
Description: Injection of steroid solution into the lumbar level
Study: NCT03501134

Intervention type: DEVICE
Intervention: NovoTTF
Description: We are studying the effect of Tumor Treating Fields (NovoTTF), for example Optune™, on the quality of life, including exercise, sleep quality, and mood, of patients with malignant glioma who plan to use the NovoTTF device.
Study: NCT04321434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperoxia

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normoxia

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser Doppler
Description: laser Doppler

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: laser Doppler
Description: laser Doppler
Study: NCT01858701

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B toric contact lens
Description: Commercially available, silicone hydrogel contact lens for correction of astigmatism

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B toric contact lens
Description: Commercially available, silicone hydrogel contact lens for correction of astigmatism

Intervention type: DEVICE
Group type: OTHER
Intervention: Comfilcon A toric contact lens
Description: Commercially available, silicone hydrogel contact lens for correction of astigmatism

Intervention type: DEVICE
Group type: OTHER
Intervention: Comfilcon A toric contact lens
Description: Commercially available, silicone hydrogel contact lens for correction of astigmatism
Study: NCT01854034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922
Description: AUY922 administered intravenously once a week at 70mg/m2
Study: NCT00726232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib was administered orally and supplied as 5 mg and 25 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib was administered orally and supplied as 5 mg and 25 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib was administered orally and supplied as 5 mg and 25 mg tablets.
Study: NCT04228367

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JuggerStitch Meniscal Repair Device
Description: Treatment of torn meniscus with JuggerStitch.